Compare Organon & Co. Common Stock (OGN) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Victoria's Secret & Co — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Victoria's Secret & Co trades at $86.8 (market cap $7.08B). The key difference: Victoria's Secret & Co is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Victoria's Secret & Co for 34 Days on average.
| OGN | VSXY | |
|---|---|---|
Market Cap | $3.62B | $7.08B |
Volume | 2,892,999 | 1,247,026 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $99.97 |
52-Week Low | $5.70 | $30.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $11.04B | $9.46B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Victoria's Secret (VSXY) trades at $88.39, down 0.23% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy, though valuation remains elevated at P/E 19.83 and P/B 7.16.
The outlook appears positive with 60% analyst buy ratings and projected net income growth to $378M in 2026. Key opportunities include international expansion and margin improvement, while risks involve rich valuation, rising costs, and competitive pressures in retail apparel. The stock trades near consensus target of $86.80 with upside potential to $101.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
